CA
NZ
UK
AU
IND
US
Natera (Nasdaq:NTRA) enters August 2026 with the widest gap in years between its operating momentum and its share price. The cell-free DNA testing company closed at $267.76, down 0.7% on the session and about 7% below the $288.04 52-week high, according to aggregated market …
Neurocrine Biosciences (Nasdaq:NBIX) posted second-quarter 2026 revenue of $959.0 million, up 39% from $687.5 million a year earlier, with GAAP diluted earnings of $1.39 a share and non-GAAP diluted earnings of $2.85. Management raised full-year Ingrezza guidance. The market's verdict arrived the following session: …
Madrigal Pharmaceuticals (Nasdaq:MDGL) published second-quarter results at last closing that cleared Wall Street's bar on both lines. Rezdiffra, resmetirom, the thyroid hormone receptor-beta agonist that in March 2024 became the first therapy the FDA approved for MASH with liver fibrosis, booked $364.3 million in …
Medline (Nasdaq:MDLN) publishes second-quarter 2026 results before the open on Wednesday 5 August, with a call at 9:30 a.m. ET. It is only the company's third report as a public business, and it arrives with the investment case pulling in two directions.
Medtronic (NYSE:MDT) closed its acquisition of SPR Therapeutics, paying $650 million in cash upfront for a private company whose lead product does something unusual in neuromodulation: it leaves nothing behind. SPR's SPRINT system delivers 60 days of peripheral nerve stimulation through a fine lead …
Insmed (Nasdaq:INSM) closed at $98.60, down 2.85% on the day and lower for a sixth consecutive session, according to aggregated market data. That leaves the Bridgewater, New Jersey company valued at about $21.4bn, still one of the largest US commercial-stage biotechs without a profit, …
Insulet Corporation (Nasdaq:PODD) reports second-quarter results with an unusually wide gap between its operating numbers and its share price. The maker of Omnipod, the tubeless patch pump taking share from tubed insulin pumps and injection therapy alike, grew first-quarter revenue 33.9% and lifted full-year …
Few medtech companies could match the raw numbers Intuitive Surgical (Nasdaq:ISRG) posted on 16 July. Second-quarter revenue rose 19% to $2.89 billion, non-GAAPEarningsreached $2.80 per diluted share, and worldwide procedures across the company's platforms grew roughly 16%. Both headline figures clearedWall Street, which had …
IQVIA Holdings (NYSE:IQV) closed at $235.13 at last closing, down 1.1% on the day. The slip looks unremarkable until you place it against the previous week. On 28 July the shares jumped 13.9% to $242.94 after the company beat the high end of its …
Jazz Pharmaceuticals (Nasdaq:JAZZ) goes into August with more riding on two dates than at any point in years. The Dublin-domiciled specialty pharma reports second-quarter results. Three weeks later, on 25 August, the FDA is due to act on a supplementalBiologicsapplication for Ziihera (zanidatamab-hrii) in …
Please wait processing your request...